格劳科斯公司（Glaukos Corp，股票代码：GKOS）周四盘中股价暴跌11.62%，主要受到多家知名投资银行大幅下调目标价的影响。
据最新消息，摩根大通（JPMorgan）对格劳科斯的目标价做出了最大幅度的调整，将其从此前的160美元大幅下调至100美元，降幅高达37.5%。与此同时，Truist Securities也下调了其目标价，从140美元下调至135美元。富国银行（Wells Fargo）更是将格劳科斯的评级从"增持"下调至"持股观望"，并将目标价从160美元大幅下调至86美元。此外，Needham虽然维持了"买入"评级，但也将目标价从176美元下调至115美元。
这些知名投资银行的一致行动引发了投资者对格劳科斯未来前景的担忧，导致其股价在盘中出现大幅下跌。分析人士指出，目标价的显著下调可能反映出分析师对公司近期业务表现或行业环境的看法发生了重大变化。格劳科斯作为一家专注于开发和商业化用于治疗青光眼的创新技术的医疗器械公司，其股价表现一直受到市场密切关注。投资者应密切关注公司接下来的公告和财报，以更好地理解这次股价调整背后的具体原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.